זיפאדהרה 405 מ"ג

국가: 이스라엘

언어: 히브리어

출처: Ministry of Health

유효 성분:

OLANZAPINE AS PAMOATE MONOHYDRATE 405 MG

제공처:

ELI LILLY ISRAEL LTD

ATC 코드:

N05AH03

약제 형태:

POWDER FOR SUSPENSION FOR INJECTION

관리 경로:

I.M

Manufactured by:

LILLY PHARMA FERT. & DISTRIB. GmbH & Co. KG

치료 그룹:

OLANZAPINE

치료 징후:

Zypadhera is indicated for the treatment of schizophrenia.The use of Zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .Zypadhera is not to be used in patients whose condition is adequately controlled with oral Zyprexa .Zypadhera is available only through a restricted program which will be conducted according to Zypadhera EU Risk Management Plan.For a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the Zypadhera Risk Management Plan. The Zypadhera Risk Management plan has been developed to enable the safe use of Zypadhera in patients, including the management of those patients who develop Post-Injection Delirium and Sedation Syndrome. In addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

승인 날짜:

2010-12-01